Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinib is a targeted therapy designed for adult patients with advanced, metastatic, or unsuitable surgical resection cholangiocarcinoma who have undergone at least one round o···【more】
Article source：Captain MedicineRelease date：2024-08-15Recommended：283
The core mechanism of Pemigatinib, a class of small molecule kinase blockers specifically targeting FGFR1, FGFR2, and FGFR3 receptors, lies in the effective inhibition of phosphory···【more】
Article source：Captain MedicineRelease date：2024-08-15Recommended：250
Pemigatinib is the world's first targeted therapy for cholangiocarcinoma.What are the drug interactions of Pemigatinib?The metabolic process of Pemigatinib may be influenced by···【more】
Article source：Captain MedicineRelease date：2024-08-15Recommended：298
Pemigatinib is a small-molecule kinase inhibitor targeting FGFR1, 2, and 3 by inhibiting phosphorylation and signaling of these receptors, thereby inhibiting tumor cell proliferati···【more】
Article source：Captain MedicineRelease date：2024-08-15Recommended：235
Pemigatinibis the world's first targeted therapy for cholangiocarcinoma for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who hav···【more】
Article source：Captain MedicineRelease date：2024-08-15Recommended：241
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemigatinib is usually given afte···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：256
Selpercatinib is a targeted drug for the treatment of RET gene mutations, which was approved by the FDA in May 2020 for the treatment of cancer patients with abnormal RET kinase mu···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：234
Venetoclax reduces the viability of cancer cells by highly selectively inhibiting the function of the Bcl-2 protein. Venetoclax has a low effect on platelets and has been approved ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：192
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by binding to the BCL-2 protein. Venetoclax is widely used in the treatment of hematological malignanci···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：223
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that can induce spontaneous apoptosis of cancer cells by specifically binding to Bcl-2 protein and reduce t···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：233
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apoptotic function of the BCL-2 protein. Indications include chronic lymphocytic leukemia, acute myeloid l···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：265
Venetoclax is the only approved inhibitor of Bcl-2, which achieves high selectivity for Bcl-2 and reduces platelet damage by introducing indole and azaindole groups, making it suit···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：228
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
